ESC 2009 Archive
Extensive news coverage of Late-Breaking Clinical Trials from the ESC 2009.
| Sunday, August 30 |
|---|
RE-LY
Stuart J. Connolly, M.D.
|
PLATO
Lars Wallentin, M.D., Ph.D.
|
OASIS
Shamir R Mehta, M.D.
|
| Monday, August 31 |
|---|
| Joint Session The European Society of Cardiology and the American Heart Association Cardiovascular Prevention: From Cells to Society How to cool the burning plaque 
Valentin Fuster, M.D., Ph.D.
|
Otamixaban withstands the test of efficacy and safety
Marc S. Sabatine, M.D., MPH
|
TRIANA
Héctor Bueno, M.D., Ph.D., FESC
|
Myocardial ischemia/reperfusion injury is mediated by leukocytic TLR2 and reduced by systemic administration of a novel anti-TLR2 antibody
Fatih Arslan, M.D.
|
Exosomes are the active cardioprotective component in MSC secretion
Dominique de Kleijn, Ph.D.
|
Chronic, low dose epoetin-? treatment following PCI significantly improves left ventricular ejection fraction in ischemic heart failure
Martin W. Bergmann, M.D.
|
C-reactive protein and all cause mortality
Borge G. Nordestgaard, M.D., D.M.Sc.
|
| Tuesday, September 1 |
|---|
MADIT-CRT Trial
 Arthur J. Moss, M.D.
|
PROTECT- Study
 Marco Metra, M.D., FESC
|
|
Joint Session: The European Society of
Cardiology and the American Heart Association Acute heart failure: why does a common problem have different outcomes in Europe and in the United States?
|
| TRITON-TIMI 38 Trial
Michelle O'Donoghue, M.D.
|
| RECORD Study
Michel Komajda
|
| Wednesday, September 2 |
|---|
Comparison between the effects of dabigatran versus warfarin in Vitamin K antagonist naïve and experienced patients with atrial fibrillation in the the  Michael D Ezekowitz
|
The 2 year outcomes of the SYNTAX Trial
 A. Pieter Kappetein, M.D., Ph.D.
|
| JUPITER
Robert J Glynn
|